Ken Griffin Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$212.22 - $292.96 $721,548 - $996,063	-3,400 Reduced 5.96%	53,600 $11.4 Million
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $10.4 Million - $15.7 Million	-53,700 Reduced 48.51%	57,000 $16 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $7.85 Million - $13 Million	45,800 Added 70.57%	110,700 $29.6 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $252,840 - $497,973	2,100 Added 3.34%	64,900 $15 Million
Q3 2023 Nov 14, 2023	SELL	$146.04 - $225.78 $8.05 Million - $12.4 Million	-55,100 Reduced 46.73%	62,800 $9.17 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $10.7 Million - $16.4 Million	52,700 Added 80.83%	117,900 $27.2 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $43.2 Million - $57.4 Million	-186,900 Reduced 74.14%	65,200 $15.8 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $9.23 Million - $46.9 Million	158,000 Added 167.91%	252,100 $73.2 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $2.29 Million - $3.01 Million	37,800 Added 67.14%	94,100 $6.12 Million

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.34B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.